129 related articles for article (PubMed ID: 30360295)
1. Re: A Retrospective Study of Treatment Persistence and Adherence to α-Blocker plus Antimuscarinic Combination Therapies, in Men with LUTS/BPH in the Netherlands.
Kaplan SA
J Urol; 2018 Nov; 200(5):919. PubMed ID: 30360295
[No Abstract] [Full Text] [Related]
2. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
[TBL] [Abstract][Full Text] [Related]
3. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
[TBL] [Abstract][Full Text] [Related]
4. Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Barkin J; Diles D; Franks B; Berner T
Can J Urol; 2015 Aug; 22(4):7914-23. PubMed ID: 26267031
[TBL] [Abstract][Full Text] [Related]
5. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
6. Current role for combination therapy in male LUTS.
Chung DE; Kaplan SA
Arch Esp Urol; 2010 Jun; 63(5):323-32. PubMed ID: 20587837
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms.
Füllhase C; Chapple C; Cornu JN; De Nunzio C; Gratzke C; Kaplan SA; Marberger M; Montorsi F; Novara G; Oelke M; Porst H; Roehrborn C; Stief C; McVary KT
Eur Urol; 2013 Aug; 64(2):228-43. PubMed ID: 23375241
[TBL] [Abstract][Full Text] [Related]
8. Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia.
Sicras-Mainar A; Navarro-Artieda R; Mora AM; Hernández M
BMC Urol; 2017 Sep; 17(1):83. PubMed ID: 28899370
[TBL] [Abstract][Full Text] [Related]
9. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
10. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
Zabkowski T; Saracyn M
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
[TBL] [Abstract][Full Text] [Related]
11. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
12. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015.
Schauer I; Madersbacher S
Curr Opin Urol; 2015 Jan; 25(1):6-11. PubMed ID: 25393269
[TBL] [Abstract][Full Text] [Related]
14. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.
Jhang JF; Liao CH; Kuo HC
Int J Clin Pract; 2014 Jun; 68(6):743-8. PubMed ID: 24471413
[TBL] [Abstract][Full Text] [Related]
15. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
17. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
Verheggen BG; Lee R; Lieuw On MM; Treur MJ; Botteman MF; Kaplan SA; Trocio JN
J Med Econ; 2012; 15(3):586-600. PubMed ID: 22332704
[TBL] [Abstract][Full Text] [Related]
18. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
20. Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Koh JS; Cho KJ; Kim HS; Kim JC
Int J Clin Pract; 2014 Feb; 68(2):197-202. PubMed ID: 24372906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
